Could a diabetes drug help beat concaine addiction?
A study by sceintists at the Unviersity of Pensylvania found that common diabetes drug Byetta plays a rule in concaine consumption. The study was published in Neuropsychopharmacology.
Daily Mail (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 12, 2016 Category: Endocrinology Source Type: news
Diabetes drug found to help beat cocaine addiction
Scientists from University of Pennsylvania discovered that Byetta, a diabetes drug that targets a hormone dealing with food consumption, can also decrease an addict's desire for cocaine. (Source: the Mail online | Health)
Source: the Mail online | Health - February 12, 2016 Category: Consumer Health News Source Type: news
New approach offered to treating cocaine addiction
An FDA-approved drug used for diabetes and obesity may also reduce cocaine dependence, new research indicates. The drug, trade name Byetta, derives from a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which regulates feeding behavior. Knowing what they did about GLP-1, the research team turned to it as a possible treatment for cocaine addicts. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 11, 2016 Category: Science Source Type: news
Glide Technologies Announces Successful Proof-of-Concept with Novel Exenatide Solid Dose Formulation
Glide Technologies has announced that they have successfully completed a pre-clinical proof-of-concept study with its novel solid dose formulation of exenatide, a GLP-1 agonist for the treatment of Type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2016 Category: Pharmaceuticals Source Type: news
Some Differences Between Once-Weekly GLP-1 AgonistsSome Differences Between Once-Weekly GLP-1 Agonists
Once-weekly GLP-1 receptor agonists dulaglutide, exenatide, and the now-withdrawn taspoglutide show the greatest reduction of HbA1c in a meta-analysis. Hypoglycemia risk is similar across the class. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 9, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Once-a-week diabetes meds are similar in safety and effectiveness
(In this Nov 8 story, corrects name of Bydureon in paragraph 10 from Byetta.) (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Weekly GLP-1RAs Compared for Type 2 Diabetes (FREE)
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Dulaglutide, once-weekly exenatide, and taspoglutide are associated with the largest reductions in hemoglobin A1c among all the weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), according to a network meta-analysis … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 8, 2015 Category: Primary Care Source Type: news
Data Support Twice Yearly Exenatide 'Minipump' for DiabetesData Support Twice Yearly Exenatide 'Minipump' for Diabetes
An investigational subdermal device that delivers the GLP-1 agonist exenatide for 6 to 12 months in patients with type 2 diabetes reduced HbA1c and lowered weight in phase 3 studies. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 29, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Implantable Exenatide Delivery Device Lowers HbA1c in T2DMImplantable Exenatide Delivery Device Lowers HbA1c in T2DM
The rationale behind the subcutaneous drug-delivery platform is to offer patients an alternative to regular life-long injections and improve patient compliance and convenience, according to study investigators. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
MassDevice.com +3 | The top 3 medtech stories for August 19, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Masimo takes over Tony Stark’s headquarters
Masimo moved its headquarters to a Hollywood-hotspot at 52 Discovery in Irvine, Calif., a location often used in films to represent upscale corporate headquarters.
The rotund glass front entrance has served as a backdrop for multiple Hollywood ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 3 Source Type: news
Diabetes: Intarcia’s implantable drug pump tops Merck’s Januvia
Intarcia Therapeutics yesterday unveiled top-line results from a year-long trial of an implantable drug pump for Type II diabetics, saying its ITCA 650 treatment proved superior to its comparator, Merck‘s (NYSE:MRK) Januvia.
Fifty-two week results from the Phase III Freedom-2 trial met all primary and secondary endpoints, “demonstrating superiority over Januvia at every measured time point,” Intarcia said. The matchstick-sized, miniature osmotic pump reduced glycated hemoglobin (HbA1c) levels and weight in patients in the study, the company said. The subcutaneous ITCA 650 is designed to deliver the ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Diabetes Drug Pumps Intarcia Therapeutics newtag Source Type: news
Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its...
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin.(PRWeb April 23, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12671977.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 24, 2015 Category: Pharmaceuticals Source Type: news
Byetta, Victoza, Bydureon: Diabetes drugs and weight loss
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - April 11, 2015 Category: Consumer Health News Source Type: news
Real-world usage and cost of exenatide and liraglutide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2015 Category: Drugs & Pharmacology Source Type: news
Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
Hundreds of Byetta lawsuits and other product liability claims involving incretin mimetic diabetes drugs are currently pending in the federal litigation underway in California.(PRWeb December 21, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12409444.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 22, 2014 Category: Pharmaceuticals Source Type: news
